Spero Therapeutics, Inc.

NasdaqGS:SPRO Lagerbericht

Marktkapitalisierung: US$63.8m

Spero Therapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Spero Therapeutics is forecast to grow earnings and revenue by 20.3% and 22.6% per annum respectively while EPS is expected to grow by 15.1% per annum.

Wichtige Informationen

20.3%

Wachstumsrate der Gewinne

15.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum27.1%
Wachstumsrate der Einnahmen22.6%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert03 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Nov 02
There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding

Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Jul 15
Insufficient Growth At Spero Therapeutics, Inc. (NASDAQ:SPRO) Hampers Share Price

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12
Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02
Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17
Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13
Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05
We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics appoints Kamal Hamed MD CMO

Sep 15

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Sep 06

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Aug 10

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Jul 04
We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Mar 17
We're Hopeful That Spero Therapeutics (NASDAQ:SPRO) Will Use Its Cash Wisely

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SPRO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/202619-90-89-882
12/31/202519-103N/A-983
12/31/202426-87N/A-573
6/30/202411817-14-14N/A
3/31/202411123-14-14N/A
12/31/202310423-33-33N/A
9/30/202378-22929N/A
6/30/202354-101212N/A
3/31/202354-2788N/A
12/31/202254-46-8-8N/A
9/30/20229-102-80-80N/A
6/30/202210-113-84-84N/A
3/31/202213-103-77-77N/A
12/31/202118-90-64-64N/A
9/30/202117-79-53-53N/A
6/30/202118-76-70-70N/A
3/31/202115-74-78-78N/A
12/31/20209-79-86-86N/A
9/30/202011-85-87-87N/A
6/30/202012-84-75-75N/A
3/31/202012-80-63-62N/A
12/31/201918-61-50-50N/A
9/30/201916-47-49-46N/A
6/30/201912-39-45-42N/A
3/31/201911-36-41-39N/A
12/31/20184-42-42-40N/A
9/30/20183-46-39-39N/A
6/30/20183-47-44-44N/A
3/31/20183-50N/A-44N/A
12/31/20172-46N/A-39N/A
9/30/20171-40N/A-36N/A
6/30/20171-35N/A-32N/A
3/31/20170-30N/A-29N/A
12/31/20160-30N/A-29N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SPRO's forecast earnings growth (20.3% per year) is above the savings rate (2.5%).

Ertrag vs. Markt: SPRO's earnings (20.3% per year) are forecast to grow faster than the US market (15.4% per year).

Hohe Wachstumserträge: SPRO's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: SPRO's revenue (22.6% per year) is forecast to grow faster than the US market (8.9% per year).

Hohe Wachstumseinnahmen: SPRO's revenue (22.6% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if SPRO's Return on Equity is forecast to be high in 3 years time

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y